Obicetrapib for High Cholesterol

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
High Cholesterol+8 MoreObicetrapib - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study whether the drug obicetrapib is effective in treating people with a history of HeFH, a condition that causes high cholesterol. The trial will be placebo-controlled, meaning some participants will receive a placebo, and double-blind, meaning neither the participants nor the researchers will know who is receiving the drug or the placebo.

Eligible Conditions
  • High Cholesterol
  • Hyperlipoproteinemia
  • Lipid Metabolism Disorder
  • Genetic Disorders, Congenital
  • Metabolic Diseases
  • Inborn Errors of Lipid Metabolism
  • Dyslipidemia

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

Study Objectives

0 Primary · 10 Secondary · Reporting Duration: Percent change from baseline to Day 84, 180, and 365 in TG

Day 180
LDL-C
Day 180
Low Density Lipoprotein-Cholesterol (LDL-C)
Day 84
Lp(a)
Day 84
non-HDL-C
Day 84
Apolipoproteins B
Day 84
HDL-C
Day 84
TC
Day 84
TG
Day 84
Total Cholesterol
Day 84
Triglycerides

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

Trial Design

2 Treatment Groups

Obicetrapib 10 mg
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

300 Total Participants · 2 Treatment Groups

Primary Treatment: Obicetrapib · Has Placebo Group · Phase 3

Obicetrapib 10 mg
Drug
Experimental Group · 1 Intervention: Obicetrapib · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Obicetrapib
2021
Completed Phase 2
~240

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: percent change from baseline to day 84, 180, and 365 in tg

Who is running the clinical trial?

NewAmsterdam PharmaLead Sponsor
7 Previous Clinical Trials
11,872 Total Patients Enrolled
5 Trials studying High Cholesterol
2,859 Patients Enrolled for High Cholesterol
Marc DitmarschStudy DirectorNewAmsterdam Pharma
3 Previous Clinical Trials
2,627 Total Patients Enrolled
3 Trials studying High Cholesterol
2,627 Patients Enrolled for High Cholesterol

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
Illinois50.0%
Virginia50.0%
How old are they?
65+100.0%
What site did they apply to?
Overlook Medical Center100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%
How many prior treatments have patients received?
1100.0%